Summary
46 / 100 · Bulios Score
What speaks for it
- Revenue grew by 59% a year over the last 3 years.
- It has no debt and holds $201.0M in cash.
- Analysts expect revenue to grow by 22% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 78% a year over 5 years. Over the last 3 years it grew by 59% a year. For the next fiscal year analysts expect revenue to grow by 22%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $340.1M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 22
- Hold 12
- Sell 0
Today's price within the analysts' price targets
The average target of $23.42 is 6.8% below today's price. 65% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
The company reports no revenue by product.
By region
- UNITED STATES 61%
- Non-US 39%
UNITED STATES brings in 61% of revenue. Non-US grew fastest, by 57% a year.
Segments in detail